IL2 and neoplasm: Earlier studies had revealed that a fusion protein consisting of IL-2 and anti-CD137 produced strong antitumor effects but was still accompanied by severe systemic toxicity (84) Thus, researchers designed the liposome-based formulation aimed at achieving rapid tumor localization with minimal systemic exposure during in vivo tests.